A commonly prescribed heart and blood pressure medication, used by tens of thousands of women across the UK, is under urgent review after a landmark study uncovered a potential link to an increased risk of cancer.
The drug, spironolactone, is frequently used to treat heart failure, high blood pressure, and oedema. It is also prescribed off-label for hormonal conditions like acne and female pattern hair loss due to its anti-androgen properties.
Concerning Findings from Taiwan
Researchers from the National Taiwan University College of Medicine analysed health data from over two million patients. Their findings, published in the journal JAMA Dermatology, revealed a startling correlation.
Women taking spironolactone were found to have a significantly higher incidence of breast cancer and cancers of the genital tract compared to those taking a different antibiotic for similar skin conditions.
The study suggests the drug's hormonal mechanism, which blocks male hormones, could be the underlying cause for this increased cancer risk.
UK Regulatory Response
In light of these findings, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a formal safety review. A spokesperson confirmed they are "carefully reviewing the publication" and will "communicate further advice as appropriate."
The MHRA has emphasised that patient safety is their highest priority and that no immediate action is required for those currently taking the medication. Patients are strongly advised not to stop taking their medicine without first consulting their GP or specialist.
What This Means for Patients
For the many women in the UK relying on this medication, this news is understandably worrying. Medical professionals are urging a cautious approach.
Key advice for patients includes:
- Do not stop taking your prescribed medication abruptly.
- Book an appointment with your doctor to discuss any concerns.
- Be aware of potential symptoms, such as new lumps, skin changes, or unusual bleeding, and report them to your GP immediately.
- Attend all routine cancer screenings, such as mammograms and cervical smears.
This review underscores the ongoing process of drug safety monitoring. While the study identifies a potential risk, more research is needed to fully understand the link. The medical community awaits the conclusions of the MHRA's investigation, which will determine if prescribing guidelines for this common drug need to change.
